IP Library Granted Patent US 8,465,725
Granted Patent B2
US 8,465,725 · App. 12/815,637 · Granted Jun 18, 2013

Process for production of heterodimers of glutamic acid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,465,725
App. No.
12/815,637
Granted
Jun 18, 2013
Kind
B2
Abstract

A manufacturing process for the preparation of radiolabeled compounds of formula (I) includes reacting compounds of formula (II) with a source of radionuclide of a halogen in the presence of an oxidant under acidic condition, wherein: *I is 123 I, 124 I, 125 I or 131 I; R is lower alkyl, optionally substituted with one or more fluorine atoms; Q is C(O), O, NR′, S, S(O) 2 , C(O) 2 , (CH 2 ) p ; Y is C(O), O, NR′, S, S(O) 2 , C(O) 2 , (CH 2 ) p ; R′ is H, C(O), S(O) 2 , C(O) 2 ; Z is H, C 1 -C 4 alkyl, benzyl, substituted benzyl or trialkylsilyl; m is 0, 1, 2, 3, 4 or 5; n is 0, 1, 2, 3, 4, 5 or 6; and p is 0, 1, 2, 3, 4, 5 or 6.

Claims (50)

1. A process for the preparation of a radiolabeled compound of formula (I)

the process comprising:

reacting a compound of formula (II) with a metal salt of *I in the presence of an oxidant under acidic conditions,

wherein

*I is 123 I, 124 I, 125 I or 131 I;

R is lower alkyl, optionally substituted with one or more fluorides;

Q is C(O), O, NR′, S, S(O) 2 , C(O) 2 , (CH 2 ) p ;

Y is O, NR′, S, S(O) 2 , C(O) 2 , (CH 2 ) p ;

R′ is H, C(O), S(O) 2 , C(O) 2 ;

Z is H, C 1 -C 4 alkyl, benzyl, substituted benzyl or trialkylsilyl;

m is 0, 1, 2, 3, 4 or 5;

n is 0, 1, 2, 3, 4, 5 or 6; and

p is 0, 1, 2, 3, 4, 5 or 6.

2. The process of claim 1 , wherein the acidic conditions comprise a pH of less than about 3.

3. The process of claim 1 , wherein R is methyl.

4. The process of claim 1 , wherein the metal salt of *I is a Group IA metal salt of *I wherein *I is 123 I, 124 I, 125 I or 131 I.

5. The process of claim 4 , wherein the metal salt is a sodium salt.

6. The process of claim 1 , wherein the oxidant comprises a peracid.

7. The process of claim 1 , wherein the reacting comprises adding an acid to the compound of formula (II) and metal salt of *I, prior to adding the oxidant.

8. The process of claim 7 , wherein the acid comprises a mineral acid or an organic acid.

9. The process of claim 8 , wherein the mineral acid is a non-halogen bearing or releasing acid.

10. The process of claim 8 , wherein the acid comprises phosphoric acid, sulfuric acid or acetic acid.

11. The process of claim 8 , wherein an amount of the acid is sufficient to maintain a pH of from 1 to 3.

12. The process of claim 1 further comprising reacting a low concentration of a cold metal iodide with the compound of formula (II), the metal salt of *I, and the oxidant.

13. The process of claim 12 , wherein the low concentration is from 0.1 to 10 μg of cold metal iodide per 50 mCi of the metal salt of *I.

14. The process of claim 13 , wherein the cold metal iodide is Na 127 I.

15. The process of claim 1 , wherein the compound of formula (I) is:

wherein:

*I is 123 I, 124 I, 125 I or 131 I; and

Z is H, C 1 -C 4 alkyl, benzyl, substituted benzyl or trialkylsilyl.

16. The process of claim 15 , wherein Z is tert-butyl.

17. The process of claim 1 , wherein the compound of formula (I) is

18. The process of claim 1 further comprising chromatographically purifying the radiolabeled compound of the formula (I).

19. The process of claim 18 further comprising adding 2-3% sodium gentisate and 5-6% ascorbate/asorbic acid at a pH of from 4.5 to 5.5 to stabilize the radiolabeled compound represented by formula (I).

20. A process for the preparation of a radiolabeled compound of formula:

the process comprising:

reacting a compound of formula

with a metal salt of *I in the presence of an oxidant under acidic conditions,

wherein:

*I is 123 I; 124 I; 125 I or 131 I;

R is lower alkyl, optionally substituted with one or more fluorides; and

Z is H, C 1 -C 4 alkyl, benzyl, substituted benzyl or trialkylsilyl.

21. The process of claim 20 , wherein the acidic conditions comprise a pH of less than about 3.

22. The process of claim 20 , wherein R is methyl.

23. The process of claim 20 , wherein the metal salt of *I is a Group IA metal salt of *I wherein *I is 123 I; 124 I, 125 I or 131 I.

24. The process of claim 23 , wherein the metal salt is a sodium salt.

25. The process of claim 20 , wherein Z is H or C 1 -C 4 alkyl.

26. The process of claim 20 , wherein Z is tert-butyl.

27. The process of claim 20 further comprising chromatographically purifying the radiolabeled compound.

28. The process of claim 20 further comprising adding 2-3% sodium gentisate and 5-6% ascorbate/asorbic acid at a pH of from 4.5 to 5.5 to stabilize the radiolabeled compound.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Dec 2, 2022
From: WELLS FARGO BANK, N.A.
To: PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC
Reel/Frame 062047/0915 →
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →
SECURITY AGREEMENT Recorded Aug 19, 2020
From: PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY LLC
To: WELLS FARGO BANK, N.A.
Reel/Frame 053538/0666 →
RELEASE OF PATENT SECURITY INTEREST Recorded Jan 18, 2013
From: NEXBANK, SSB (AS COLLATERAL AGENT)
To: MOLECULAR INSIGHT PHARMACEUTICALS, INC.
Reel/Frame 029660/0618 →
MERGER Recorded Jun 6, 2011
From: MOLECULAR INSIGHT PHARMACEUTICALS, INC.
To: MOLECULAR INSIGHT PHARMACEUTICALS, INC.
Reel/Frame 026396/0273 →
GRANT OF SECURITY INTEREST IN PATENT RIGHTS Recorded May 26, 2011
From: MOLECULAR INSIGHT PHARMACEUTICALS, INC.
To: NEXBANK, SSB, A TEXAS-CHARTERED SAVINGS BANK, AS COLLATERAL AGENT
Reel/Frame 026347/0233 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2010
From: BABICH, JOHN W.; ZIMMERMAN, CRAIG; MARESCA, KEVIN P.
To: MOLECULAR INSIGHT PHARMACEUTICALS, INC.
Reel/Frame 025215/0674 →